Piper Jaffray Cos. set a $49.00 price target on CoLucid Pharmaceuticals Inc. (NASDAQ:CLCD) in a research report released on Friday morning. The brokerage currently has a an overweight rating on the biopharmaceutical company’s stock.
A number of other brokerages also recently issued reports on CLCD. Ladenburg Thalmann set a $57.00 price objective on CoLucid Pharmaceuticals and gave the company a buy rating in a research note on Monday, September 19th. Stifel Nicolaus boosted their price objective on CoLucid Pharmaceuticals from $27.00 to $30.00 and gave the company a buy rating in a research note on Monday, September 19th. Finally, Zacks Investment Research downgraded CoLucid Pharmaceuticals from a hold rating to a sell rating in a research note on Friday, September 9th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus target price of $33.05.
Shares of CoLucid Pharmaceuticals (NASDAQ:CLCD) opened at 36.96 on Friday. The stock has a 50 day moving average price of $22.05 and a 200-day moving average price of $11.05. The firm’s market capitalization is $566.74 million. CoLucid Pharmaceuticals has a 52-week low of $3.60 and a 52-week high of $39.27.
CoLucid Pharmaceuticals (NASDAQ:CLCD) last announced its quarterly earnings data on Wednesday, August 10th. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.84) by $0.22. Equities analysts forecast that CoLucid Pharmaceuticals will post ($3.91) EPS for the current year.
In related news, CEO Thomas P. Mathers sold 6,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 14th. The stock was sold at an average price of $23.32, for a total transaction of $139,920.00. Following the transaction, the chief executive officer now directly owns 244,714 shares of the company’s stock, valued at approximately $5,706,730.48. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Thomas P. Mathers sold 6,502 shares of the company’s stock in a transaction that occurred on Wednesday, September 7th. The stock was sold at an average price of $21.72, for a total value of $141,223.44. Following the transaction, the chief executive officer now directly owns 256,916 shares in the company, valued at $5,580,215.52. The disclosure for this sale can be found here. 13.70% of the stock is owned by insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of CLCD. Societe Generale purchased a new position in CoLucid Pharmaceuticals during the second quarter worth $464,000. FMR LLC purchased a new position in CoLucid Pharmaceuticals during the second quarter worth $554,000. Finally, Vanguard Group Inc. increased its position in CoLucid Pharmaceuticals by 1.2% in the second quarter. Vanguard Group Inc. now owns 76,242 shares of the biopharmaceutical company’s stock worth $623,000 after buying an additional 900 shares during the period. 30.47% of the stock is currently owned by institutional investors and hedge funds.
CoLucid Pharmaceuticals Company Profile
CoLucid Pharmaceuticals, Inc is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies.
Receive News & Ratings for CoLucid Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CoLucid Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.